Wegovy is only obesity drug linked to reduced death risk, BMJ analysis finds

A BMJ network meta-analysis of 262 trials found Wegovy was the only obesity drug associated with reduced risks of death, heart attack, and heart failure.medicalxpress+1
Eli Lilly's Mounjaro reduced heart failure risk but showed no broader cardiovascular protection and caused the most lean mass loss.medicalxpress
Novo Nordisk's cardiovascular edge has commercial implications, as Wegovy's heart-health indication enabled Medicare coverage starting July 1.prnewswire

A comprehensive analysis published in The BMJ on July 8 found that subcutaneous semaglutide — marketed as Wegovy — is the only obesity drug associated with reduced risks of death, heart attack, and heart failure, reinforcing Novo Nordisk's position in the competitive weight-loss drug market even as the study cast doubt on the broader cardiovascular promise of the drug class.

Semaglutide Alone Shows Heart Benefits

The network meta-analysis, which reviewed 262 randomized controlled trials involving nearly 100,000 participants, concluded that despite producing substantial weight loss, most obesity drugs — including Eli Lilly's tirzepatide (Mounjaro) — do not meaningfully improve quality of life or demonstrate cardiovascular benefits at one year. Subcutaneous semaglutide was the sole exception, associated with a 19% reduced risk of death from any cause, a 28% reduction in heart attacks, and a 57% reduction in heart failure. Tirzepatide showed a 51% reduction in heart failure risk but did not demonstrate broader cardiovascular protection.medicalxpress+1

The findings arrive weeks after Novo Nordisk presented new post hoc analyses from its landmark SELECT trial at the American Diabetes Association's 2026 Scientific Sessions in New Orleans. Those analyses showed semaglutide 2.4 mg reduced the incidence of obstructive sleep apnea by 52% and lowered asthma-related adverse outcomes by 42% in patients with established cardiovascular disease and obesity.biospace+1

Growing Evidence Beyond Weight Loss

The SELECT trial, which enrolled 17,604 adults across 41 countries, originally demonstrated that Wegovy reduced major adverse cardiovascular events by 20% compared with placebo — findings that led the FDA to approve a cardiovascular indication for the drug in 2024. A separate real-world study published in early 2026 found semaglutide was associated with a 29% lower risk of major cardiovascular events compared with tirzepatide in patients with obesity and established heart disease.fda+2

The BMJ authors cautioned that most trials had relatively short follow-up periods and that greater weight loss was "consistently accompanied by higher rates of side effects and treatment discontinuation." They concluded that treatment decisions "should be individualized, balancing expected benefits, harms, treatment burden, costs, availability, and patient preferences".medicalxpress

Market Implications

The cardiovascular distinction carries commercial weight. Beginning July 1, 2026, eligible Medicare beneficiaries gained access to Wegovy through the Medicare GLP-1 Bridge program at a $50 monthly copay, with the drug's heart-health indication enabling coverage that federal law otherwise prohibits for weight-loss medications. Wegovy pill prescriptions have already surpassed three million since the oral formulation launched in early 2026.prnewswire+1

Sources (27)